Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21756735 | 0.90 | ALDH1A1 (0.59) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21756724 | 0.81 | ROCK2 (0.48) | ALDH1A1LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL31013605 | 0.81 | ROCK2 (0.48) | ALDH1A1LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL29328525 | 0.81 | P2RX7 (0.43) | MAPTTP53 | |
| SCHEMBL21756738 | 0.81 | HPGD (0.55) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL29328527 | 0.80 | KMT2A (0.52) | ALDH1A1LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL21756739 | 0.79 | MMP13 (0.62) | ALDH1A1LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL29328528 | 0.79 | MMP13 (0.60) | ALDH1A1HSD17B10 | |
| SCHEMBL10782201 | 0.74 | ALDH1A1 (0.55) | ALDH1A1TP53KMT2A | |
| SCHEMBL31013604 | 0.74 | ROCK2 (0.58) | ALDH1A1LMNASMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043601-B2 | N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2024-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043601-B2 | N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatment using same | BAK1, NAAA, CASP3 | ALDH1A1 1578/4885LMNA 3695/4885SMN1; SMN2 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.